Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Business Wire

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
From Arcus Biosciences
Via Business Wire
Tickers RCUS
TMCI Deadline: Rosen Law Firm Urges Treace Medical Concepts, Inc. (NASDAQ: TMCI) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
Tickers TMCI
DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
Announcing Balaji Karumanchi as Founder & CEO of Excelhire – The AI-Agentic Hiring Intelligence Platform
From Excelhire
Via Business Wire
Introducing Tempus One in the EHR with Integrated Guidelines
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers PTGX TAK
Research Presented by The US Oncology Network at ASCO 2025 Demonstrates Significant Cost Savings in Community Oncology Setting with Pharmacist-Driven Interventions
From The US Oncology Network
Via Business Wire
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
From Beijing Avistone Biotechnology Co., Ltd
Via Business Wire
University of Phoenix Announces 2025 UOPX Faculty of the Year Award Recipients
From University of Phoenix
Via Business Wire
BIOSIG TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of BioSig Technologies, Inc. - BSGM
From Kahn Swick & Foti, LLC
Via Business Wire
Tickers BSGM
HELIOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Heliogen, Inc. - HLGN
From Kahn Swick & Foti, LLC
Via Business Wire
Tickers HLGN OTC
SIGNING DAY SPORTS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Signing Day Sports, Inc. - SGN
From Kahn Swick & Foti, LLC
Via Business Wire
Tickers SGN
INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Broadmark Realty Capital Inc., Ready Capital Corporation, Others and Announces Opportunity for Investors with Substantial Losses to Lead Lawsuit – BRMK; RC
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
URGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Tickers URGN
Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
ispace Completes Success 8 of Mission 2 Milestones
From ispace, inc.
Via Business Wire
In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions
From Guardant Health, Inc.
Via Business Wire
Tickers GH
New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer
From Genentech
Via Business Wire
Tickers RHHBY
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
High School Students Named Best in America at the Council for Economic Education’s 2025 National Economics Challenge
From Council for Economic Education
Via Business Wire
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
From Novocure
Via Business Wire
Tickers NVCR
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial
From Daiichi Sankyo
Via Business Wire
Mythic Therapeutics Presents Compelling Efficacy Data from its Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Novel cMET- ADC, MYTX-011, in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Mythic Therapeutics
Via Business Wire
ConcertAI Provides Intelligent Automation of ASCO® Guidelines into its Generative and Agentic AI Precision Suite™ and CancerLinQ® SmartLinQ™ Solutions
From ConcertAI
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.